TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37740179

Group type: EXPERIMENTAL
Intervention: KSHV infection of primary lymphatic endothelial cells (LECs)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Knock-down of STC1 or FLT4 in LECs
Number of subjects: 19
Study: 37740419

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) associated with the best medical treatment (BMT)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 488
Study: 37740442

Group type: EXPERIMENTAL
Intervention: internet-based cognitive behaviour therapy (iCBT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: online discussion forum (ODF)
Number of subjects: 144
Study: 37740448

Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone acetate 1 mL (40 mg) plus 2 mL lidocaine (1%))
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (1 mL saline and 2 mL lidocaine)
Number of subjects: 31
Study: 37740554

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (35 mg/kg) plus 1200 mg/day of linezolid for 28 days, then reduced to 600 mg/day
Number of subjects: 30
Study: 37740581

Group type: EXPERIMENTAL
Intervention: GP40141 (3 ug × kg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Reference romiplostim
Number of subjects: 56
Study: 37740588

Group type: EXPERIMENTAL
Intervention: Rituximab, lenalidomide, and ibrutinib (R2I)
Number of subjects: 0
Study: 37740611

Group type: EXPERIMENTAL
Intervention: AZD4017 (selective 11β-HSD1 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urinary (5αTHF + THF)/THE ratio
Number of subjects: 0
Study: 37740725

Group type: COMPARATOR
Intervention: Maternal total CB-PTSS score at T1
Number of subjects: 0
Study: 37740871

Group type: EXPERIMENTAL
Intervention: Ultra Rapid Lispro (URLi) during the maintenance period
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ultra Rapid Lispro (URLi)
Number of subjects: 31
Study: 37740874

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss treatment (BWL) for 24 weeks
Number of subjects: 32
Study: 37740923

Group type: COMPARATOR
Intervention: Sparse MC-FC coupling index
Number of subjects: 137

Group type: COMPARATOR
Intervention: Abnormal coupling strength
Number of subjects: 137
Study: 37740921

Group type: EXPERIMENTAL
Intervention: Female mutation carriers
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Symptomatic female carriers
Number of subjects: 325

Group type: COMPARATOR
Intervention: PiB PET and established CSF AD markers
Number of subjects: 325
Study: 37740926

Group type: EXPERIMENTAL
Intervention: Single dose of naturally selected anti-CD7 CAR (NS7CAR) T cells at three levels: a low dose (5 × 10^5 cells), a medium dose (1 × 10^6 cells), and a high dose (2 × 10^6 cells).
Number of subjects: 60
Study: 37740931

Group type: EXPERIMENTAL
Intervention: Venetoclax (300, 600, 800, 900, or 1200 mg)
Number of subjects: 117
Study: 37740952

Group type: EXPERIMENTAL
Intervention: Endothelial damage inhibitor (EDI)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Full electrolyte solution (FES)
Number of subjects: 11
Study: 37741105

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1426

Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 1426
Study: 37741273

Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg intravenously every 4 weeks, palbociclib 125 mg orally once daily for 3 weeks per cycle, and anastrozole 1 mg orally once daily for five 4-week cycles.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg intravenously every 4 weeks, palbociclib 100 mg orally once daily for 3 weeks per cycle, and anastrozole 1 mg orally once daily for five 4-week cycles.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nivolumab, palbociclib, and anastrozole (both dosage groups).
Number of subjects: 21
Study: 37741507

Group type: EXPERIMENTAL
Intervention: digital cognitive behavioural therapy for insomnia (dCBT-I)
Number of subjects: 308

Group type: COMPARATOR
Intervention: sleep hygiene education (SHE)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: dCBT-I
Number of subjects: 308

Group type: COMPARATOR
Intervention: SHE
Number of subjects: 308
Study: 37741521

Group type: EXPERIMENTAL
Intervention: S-LANSS interview
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: LANSS examination
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: S-LANSS self-completed
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: S-LANSS
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: S-LANSS scores
Number of subjects: 161
Study: 37741832

Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deletion of Atg16l1 in engineered murine colon cancer organoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATG16L1 deficiency
Number of subjects: 0
Study: 37741921

Group type: EXPERIMENTAL
Intervention: Fexofenadine plus ramipril
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ramipril only (Control)
Number of subjects: 61
Study: 37741968

Group type: EXPERIMENTAL
Intervention: ThermoDox® with focused ultrasound-induced hyperthermia (Arm B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional doxorubicin alone (Arm A)
Number of subjects: 0
Study: 37741988

Group type: EXPERIMENTAL
Intervention: Exploratory laparotomy (ex-lap)
Number of subjects: 73
Study: 37742023

Group type: EXPERIMENTAL
Intervention: Kedo-S-Square rotary system
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fanta AF™ Baby rotary system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual K-file
Number of subjects: 60
Study: 37742131

Group type: EXPERIMENTAL
Intervention: Freeze-all strategy with postponement of embryo transfer
Number of subjects: 856

Group type: COMPARATOR
Intervention: Fresh transfer strategy
Number of subjects: 856
Study: 37742328

Group type: EXPERIMENTAL
Intervention: Statin plus ascorbic acid (atorvastatin 80-mg the day before, atorvastatin 40-mg two hours before, and atorvastatin 40-mg for two days after CECT; plus ascorbic acid 500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (two tablets of placebo once/daily before the procedure and for another 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin plus ascorbic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37742617

Group type: EXPERIMENTAL
Intervention: Acute placental abnormalities
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Chronic placental abnormalities (two or more lesions)
Number of subjects: 500
Study: 37742653

Group type: EXPERIMENTAL
Intervention: Network Medicine approach to redefine dementia treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current anti-amyloid interventions
Number of subjects: 0
Study: 37742734

Group type: EXPERIMENTAL
Intervention: Drug-eluting device treatment
Number of subjects: 750
Study: 37742741

Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Number of subjects: 4717
Study: 37742745

Group type: EXPERIMENTAL
Intervention: NAFLD (n=273 after PSM)
Number of subjects: 1496
Study: 37742797

Group type: EXPERIMENTAL
Intervention: High-dose carotenoid juice intervention (12 ounces juice, 8 mg total carotenoids/d)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Moderate-dose carotenoid juice intervention (6 ounces juice, 4 mg total carotenoids/d)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Baseline skin carotenoids
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Other variables (self-categorized race/ethnicity, biological sex, baseline body fat, body mass index, skin melanin, sun exposure)
Number of subjects: 106
Study: 37742911

Group type: EXPERIMENTAL
Intervention: Aprocitentan, a dual endothelin-1 receptor antagonist
Number of subjects: 0
Study: 37743037

Group type: EXPERIMENTAL
Intervention: Triple combination therapy with vedolizumab (300 mg on day 1, weeks 2 and 6, then every 8 weeks), adalimumab (160 mg on day 2, 80 mg at week 2, then 40 mg every 2 weeks), and methotrexate (15 mg weekly)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Triple combination therapy
Number of subjects: 55
Study: 37743116

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 356
Study: 37743153

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with lemon essential oil (n = 21)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with peppermint essential oil (n = 21)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (pure sweet almond oil) (n = 21)
Number of subjects: 63
Study: 37743180

Group type: EXPERIMENTAL
Intervention: Selinexor dose reductions (median dose 71.4 mg/wk)
Number of subjects: 195
Study: 37743478

Group type: EXPERIMENTAL
Intervention: ADRD-PC program (1) dementia-specific palliative care, (2) standardized caregiver education, (3) transitional care
Number of subjects: 424

Group type: COMPARATOR
Intervention: Publicly available educational material on dementia caregiving (Control)
Number of subjects: 424
Study: 37743486

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) administered at a continuous infusion rate of 0.2 µg/kg/h until the end of dural closure.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (control group) administered in an identical volume and setting.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 0
Study: 37743489

Group type: EXPERIMENTAL
Intervention: Green-MED diet (including green tea 3-4 cups/day and Mankai 500-ml green shake)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Mediterranean (MED) diet (including 28 g walnuts/day)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Healthy dietary guidelines
Number of subjects: 256
Study: 37743503

Group type: EXPERIMENTAL
Intervention: Research-grade hNPC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical-grade hNPC (CNS10-NPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CNS10-NPC
Number of subjects: 0
Study: 37743665

Group type: EXPERIMENTAL
Intervention: Hyperoxia
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pregnancies without FGR
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pregnancies with FGR
Number of subjects: 19
Study: 37744345

Group type: EXPERIMENTAL
Intervention: Nivolumab with or without ipilimumab combined with a single fraction of SBRT
Number of subjects: 84
Study: 37744351

Group type: EXPERIMENTAL
Intervention: Complement factor D (CFD) expression during the inflammatory phase
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Complement factor D (CFD) expression during the proliferative phase
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Regulation of collagen type I (Col1a1) expression
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fibroblast migration
Number of subjects: 68
Study: 37744662

Group type: EXPERIMENTAL
Intervention: Benzodiazepine-Free anesthesia during cardiac surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzodiazepine administration during cardiac surgery
Number of subjects: 0
Study: 37744732

Group type: EXPERIMENTAL
Intervention: HBV therapeutics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 37744940

Group type: EXPERIMENTAL
Intervention: First-line cryoballoon ablation
Number of subjects: 703

Group type: COMPARATOR
Intervention: First-line antiarrhythmic drugs (AADs)
Number of subjects: 703
Study: 37744975

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) mood induction
Number of subjects: 0
Study: 37745024

Group type: EXPERIMENTAL
Intervention: sIPV (inactivated poliovirus vaccine derived from the Sabin strain)
Number of subjects: 400

Group type: COMPARATOR
Intervention: wIPV (inactivated poliovirus vaccine derived from wild strain)
Number of subjects: 400
Study: 37745030

Group type: EXPERIMENTAL
Intervention: Chronic lung disease (CLD)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Psychosocial factors (stress, depression, anxiety)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Stress, smoking habits, boredom, taste, and social influence
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Mediation analysis
Number of subjects: 263

Group type: COMPARATOR
Intervention: Respiratory symptoms
Number of subjects: 263
Study: 37745092

Group type: EXPERIMENTAL
Intervention: Xlimus drug-eluting stent
Number of subjects: 177

Group type: COMPARATOR
Intervention: Synergy drug-eluting stent
Number of subjects: 177
Study: 37745109

Group type: EXPERIMENTAL
Intervention: Premature CAD patients undergoing PCI
Number of subjects: 6171
Study: 37745159

Group type: EXPERIMENTAL
Intervention: Mim8 (denecimig), single subcutaneous dose
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo, single subcutaneous dose
Number of subjects: 138
Study: 37745288

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin daily
Number of subjects: 15480

Group type: EXPERIMENTAL
Intervention: 1 g omega-3 fatty acids daily
Number of subjects: 15480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15480
Study: 37745371

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg twice daily for 12 days (50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days)
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1175
Study: 37745479

Group type: EXPERIMENTAL
Intervention: High-dose propofol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-dose propofol
Number of subjects: 24
Study: 37745604

Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 47

Group type: COMPARATOR
Intervention: White participants
Number of subjects: 47
Study: 37745646

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Non-Hispanic patients
Number of subjects: 2099
Study: 37745913

Group type: EXPERIMENTAL
Intervention: Nabiximols
Number of subjects: 0
Study: 37745914

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFN-alemtuzumab
Number of subjects: 0
Study: 37746068

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessed with the Short-Form Health Survey-36 (SF-36)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Post-traumatic Stress Disorder (PTSD) assessed with the Impact of Event Scale-Revised (IES-R)
Number of subjects: 33
Study: 37746613

Group type: EXPERIMENTAL
Intervention: Integrated robotic gastrectomy (IRG)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional laparoscopic gastrectomy (CLG)
Number of subjects: 140
Study: 37746735

Group type: EXPERIMENTAL
Intervention: Brensocatib 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brensocatib 10 mg, 25 mg, and Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brensocatib 10 mg and 25 mg
Number of subjects: 0
Study: 37747057

Group type: EXPERIMENTAL
Intervention: Homebound Elderly People Psychotherapeutic Intervention (HEPPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 0
Study: 37747168

Group type: EXPERIMENTAL
Intervention: 24-hour intravenous administration of antibiotics
Number of subjects: 104

Group type: COMPARATOR
Intervention: 24-hour oral administration of antibiotics
Number of subjects: 104
Study: 37747275

Group type: EXPERIMENTAL
Intervention: Transbronchial microwave ablation (MWA)
Number of subjects: 30
Study: 37747318

Group type: EXPERIMENTAL
Intervention: Fitness tracker (FitBit) with walk step reminders through an mHealth application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37747427

Group type: EXPERIMENTAL
Intervention: Statin therapy (preoperative use)
Number of subjects: 8116
Study: 37747499

Group type: EXPERIMENTAL
Intervention: Continuous paravertebral nerve block (PVB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous paravertebral and intercostal nerve block (PVB/ICB)
Number of subjects: 70
Study: 37747626

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 3452

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 3452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3452

Group type: EXPERIMENTAL
Intervention: Filgotinib
Number of subjects: 3452
Study: 37747734

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy including ABPM service, EHR tools, clinician education, nurse training, patient information handouts.
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy.
Number of subjects: 1186
Study: 37747893

Group type: EXPERIMENTAL
Intervention: Active VR
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Passive VR
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 14
Study: 37747970

Group type: EXPERIMENTAL
Intervention: Mental health intervention including case management, psychotropic medication consultation, and psychotherapy elements.
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Mental health intervention
Number of subjects: 171

Group type: COMPARATOR
Intervention: Enhanced usual care control
Number of subjects: 171
Study: 37748109

Group type: EXPERIMENTAL
Intervention: Nine-week trastuzumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-year trastuzumab treatment
Number of subjects: 0
Study: 37748124

Group type: EXPERIMENTAL
Intervention: Prophylactic Radiation Therapy (RT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 78
Study: 37748181

Group type: EXPERIMENTAL
Intervention: icodec with app
Number of subjects: 1085

Group type: COMPARATOR
Intervention: OD analogues (insulin degludec, insulin glargine U100, or insulin glargine U300)
Number of subjects: 1085
Study: 37748219

Group type: EXPERIMENTAL
Intervention: Phenocluster-specific risk factors for hospital mortality
Number of subjects: 2864

Group type: EXPERIMENTAL
Intervention: Supervised model for identifying risk factors
Number of subjects: 2864
Study: 37748493

Group type: EXPERIMENTAL
Intervention: COVID-19 patients (n=259)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Non-COVID-19 controls (n=52)
Number of subjects: 259
Study: 37748693

Group type: EXPERIMENTAL
Intervention: Avelumab Q2W (10 mg/kg every 2 weeks)
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Avelumab QW (10 mg/kg once weekly for 12 weeks, then Q2W)
Number of subjects: 1214

Group type: COMPARATOR
Intervention: Chemotherapy (platinum-based doublet)
Number of subjects: 1214
Study: 37748803

Group type: EXPERIMENTAL
Intervention: Systematic screening every 2 months for 2 years
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 168
Study: 37748849

Group type: EXPERIMENTAL
Intervention: Empiric antibiotic use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advancement of feeds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration of probiotics
Number of subjects: 0
Study: 37748954

Group type: EXPERIMENTAL
Intervention: Supplemental optoacoustic ultrasound (OA/US)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gray-scale ultrasound (US) alone
Number of subjects: 0
Study: 37749441

Group type: EXPERIMENTAL
Intervention: QmfrVEP measurements using four LED-based checkerboard stimulators
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: QmfrVEP measurements in glaucoma patients
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High SNR values
Number of subjects: 10
Study: 37749523

Group type: EXPERIMENTAL
Intervention: Physiotherapist-led mixed exercise programme for 12 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Physiotherapist-led mixed exercise programme + occupational therapist-led cognitive skills training for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 120
Study: 37749566

Group type: EXPERIMENTAL
Intervention: Fully immersive head-mounted display (HMD) session
Number of subjects: 32

Group type: COMPARATOR
Intervention: Semi-immersive GRAIL session
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Optic flow speed manipulation (slow and fast)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fully immersive VR while walking on a self-paced treadmill
Number of subjects: 32
Study: 37749601

Group type: EXPERIMENTAL
Intervention: Guided Self-Determination counselling program
Number of subjects: 13
Study: 37749631

Group type: EXPERIMENTAL
Intervention: Endotracheal aspirates (ETA)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Concordance between ETA and BAL
Number of subjects: 79
Study: 37749635

Group type: EXPERIMENTAL
Intervention: Practice coaching intervention for HIV testing only
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Practice coaching intervention for HIV/HCV testing
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control condition providing information only
Number of subjects: 51
Study: 37749876

Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioral treatment for insomnia
Number of subjects: 74
Study: 37750084

Group type: EXPERIMENTAL
Intervention: Vari-pad compression garment worn for 4 weeks
Number of subjects: 18
Study: 37750105

Group type: EXPERIMENTAL
Intervention: Presurgical and postsurgical nurse interventions (PROCESS-VALVE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face-to-face postsurgical consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone postsurgical consultation
Number of subjects: 0
Study: 37750183

Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg once daily
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 37750406

Group type: EXPERIMENTAL
Intervention: vonoprazan 10 mg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: vonoprazan 40 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 207
Study: 37750555

Group type: EXPERIMENTAL
Intervention: Nonhemorrhagic stroke
Number of subjects: 21820

Group type: EXPERIMENTAL
Intervention: Heart failure admission
Number of subjects: 21820

Group type: EXPERIMENTAL
Intervention: Incident cancer
Number of subjects: 21820

Group type: EXPERIMENTAL
Intervention: Noncoronary revascularization
Number of subjects: 21820

Group type: EXPERIMENTAL
Intervention: Myocardial infarction with urgent CRV procedure
Number of subjects: 21820

Group type: EXPERIMENTAL
Intervention: Urgent/nonurgent CRV procedure without myocardial infarction
Number of subjects: 21820